Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,101,582 papers from all fields of science
Search
Sign In
Create Free Account
LDK378
Known as:
LDK 378
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
ceritinib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors.
Hong Chen
,
Ridong Li
,
Xianling Ning
,
Xuyang Zhao
,
Yan Jin
,
Yuxin Yin
European journal of medicinal chemistry
2019
Corpus ID: 181952560
Review
2019
Review
2019
Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer
D. Rocco
,
Ciro Battiloro
,
L. Della Gravara
,
C. Gridelli
Drug Safety
2019
Corpus ID: 58622348
The chimeric protein echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase, resulting from the…
Expand
2017
2017
Rhabdomyosarcoma cells are susceptible to cell death by LDK378 alone or in combination with sorafenib independently of anaplastic lymphoma kinase status
N. Dolgikh
,
S. Fulda
Anti-Cancer Drugs
2017
Corpus ID: 3553454
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that is often overexpressed in rhabdomyosarcoma (RMS). However…
Expand
2016
2016
Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors.
Raghavendra Achary
,
Jeong In Yun
,
+13 authors
P. Kim
Bioorganic & Medicinal Chemistry
2016
Corpus ID: 25597869
2016
2016
Crizotinib Primary Resistance Overcome by Ceritinib in a Patient with ALK-Rearranged Non-Small Cell Lung Cancer
F. Facchinetti
,
C. Caramella
,
+8 authors
B. Besse
Tumori
2016
Corpus ID: 12626694
We report on the case of a patient affected by advanced non-small cell lung cancer (NSCLC) harboring an anaplastic lymphoma…
Expand
2015
2015
Successful implementation of a novel trial model: The Signature program.
J. Peguero
,
J. Knost
,
+16 authors
S. Piha-Paul
2015
Corpus ID: 78972479
106 Background: Here we describe 8 ongoing single agent clinical protocols under Novartis’ “Signature” program involving…
Expand
2014
2014
BM-32CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL
A. Shaw
,
R. Mehra
,
+18 authors
Dong-Wan Kim
2014
Corpus ID: 75452835
BACKGROUND: Ceritinib is an ALK inhibitor (ALKi) recently approved for patients with ALK+ advanced NSCLC. Efficacy and safety…
Expand
2012
2012
First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.
R. Mehra
,
D. Camidge
,
+12 authors
A. Shaw
2012
Corpus ID: 79632606
3007 Background: LDK378 is a novel, potent and selective small molecule anaplastic lymphoma kinase (ALK) inhibitor (IC50 0.00015…
Expand
2012
2012
Istorinės LDK teisės aidas moderniojoje Lietuvos teisėje
Mindaugas Maksimaitis
2012
Corpus ID: 157819944
Upon reinstitution of the Lithuanian state in the beginning of the twentieth century, some people reflected back to the times…
Expand
2011
2011
Pendekatan Kaunseling mengikut Pendekatan Psikologi Kognitif Ad-Din dalam Modul Latihan Dalam Kumpulan: Kerja Lapangan bersama dengan Anak Yatim
Madihie Amalia
,
Tan Hua Khim
,
A. Rosliza
,
Alis Norzaliza
2011
Corpus ID: 190734818
Kursus Tamadun Islam dan Tamadun Asia (TITAS) merupakan kursus generik yang perlu diambil oleh semua pelajar di universiti tanpa…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE